Steven A. Rosenberg is one of the founding architects of modern cancer immunotherapy and among the most influential surgeon-scientists in the history of oncology. He is Chief of the Surgery Branch at the U.S. National Cancer Institute in Bethesda, a position he has held for five decades, and a Professor of Surgery at the Uniformed Services University of the Health Sciences and the George Washington University, with additional academic appointments at the Karolinska Institute.
Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He has also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. His recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.
For these achievements, Dr. Rosenberg has received the highest honors in medicine and science, including the American Cancer Society Medal of Honor, and the National Medal of Technology and Innovation. A member of the National Academy of Medicine, he has authored more than 1,200 scientific publications and remains one of the most cited clinician-scientists globally.
The 100 Most Influential People in Oncology in 2025 recognizes the changemakers in cancer care who have helped shape current practice in oncology and continue to drive innovation and research towards better outcomes, advocacy, philanthropy, leadership and education. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential People in Oncology in 2025 and stay tuned for the results of special category nominations to be announced.
